iRadimed Corporation (NASDAQ:IRMD) vs. Masimo Corporation (MASI) Financial Comparison

iRadimed Corporation (NASDAQ: IRMD) and Masimo Corporation (NASDAQ:MASI) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, profitability, dividends, analyst recommendations, earnings, institutional ownership and valuation.

Insider & Institutional Ownership

15.9% of iRadimed Corporation shares are held by institutional investors. Comparatively, 84.4% of Masimo Corporation shares are held by institutional investors. 60.1% of iRadimed Corporation shares are held by insiders. Comparatively, 16.6% of Masimo Corporation shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Earnings & Valuation

This table compares iRadimed Corporation and Masimo Corporation’s revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio EBITDA Earnings Per Share Price/Earnings Ratio
iRadimed Corporation $24.35 million 4.32 $4.51 million $0.24 41.04
Masimo Corporation $730.06 million 5.95 $182.11 million $6.14 13.61

Masimo Corporation has higher revenue and earnings than iRadimed Corporation. Masimo Corporation is trading at a lower price-to-earnings ratio than iRadimed Corporation, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares iRadimed Corporation and Masimo Corporation’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
iRadimed Corporation 11.61% 8.98% 7.69%
Masimo Corporation 45.90% 23.45% 16.22%

Analyst Ratings

This is a summary of current ratings and target prices for iRadimed Corporation and Masimo Corporation, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
iRadimed Corporation 0 0 1 0 3.00
Masimo Corporation 0 3 3 0 2.50

iRadimed Corporation presently has a consensus price target of $12.00, indicating a potential upside of 21.83%. Masimo Corporation has a consensus price target of $96.25, indicating a potential upside of 15.16%. Given iRadimed Corporation’s stronger consensus rating and higher probable upside, equities research analysts plainly believe iRadimed Corporation is more favorable than Masimo Corporation.

Risk and Volatility

iRadimed Corporation has a beta of 1.51, suggesting that its stock price is 51% more volatile than the S&P 500. Comparatively, Masimo Corporation has a beta of 0.8, suggesting that its stock price is 20% less volatile than the S&P 500.

Summary

Masimo Corporation beats iRadimed Corporation on 9 of the 14 factors compared between the two stocks.

About iRadimed Corporation

IRADIMED CORPORATION (IRADIMED) develops, manufactures, markets and distributes Magnetic Resonance Imaging (MRI) compatible products, and provides non-magnetic intravenous (IV) infusion pump systems. The Company operates through development, manufacture and sale of MRI compatible products and IV infusion pump systems for use by hospitals and acute care facilities during MRI procedures segment. Its MRidium MRI compatible IV infusion pump system has been designed with a non-magnetic ultrasonic motor, non-ferrous part and other features in order to deliver anesthesia and other IV fluids during various MRI procedures. MRI compatible IV infusion pump system includes the 3860+ MRI compatible IV infusion pump, single-use IV tubing sets, a non-magnetic pole and a lithium battery. In addition, it offers optional upgrade systems, including the 3865 Remote Display/Control, 3861 Side Car, Dose Error Reduction System (DERS) and SpO2 monitor.

About Masimo Corporation

Masimo Corporation is a medical technology company that develops, manufactures and markets a range of non-invasive patient monitoring technologies. The Company’s business is Measure-through Motion and Low Perfusion pulse oximetry monitoring, known as Masimo Signal Extraction Technology (SET) pulse oximetry. Its product offerings include non-invasive monitoring of blood constituents with an optical signature, optical organ oximetry monitoring, electrical, brain function monitoring, acoustic respiration monitoring and exhaled gas monitoring. In addition, the Company has developed the Root patient monitoring and connectivity platform, the Radical-7 bedside and portable patient monitor, and the Radius-7 wearable wireless patient monitor. It offers Patient SafetyNet remote patient surveillance monitoring system, which allows patients to be monitored through a personal computer-based monitor or by care providers through their pagers, voice-over-Internet Protocol (IP) phones or smartphones.

What are top analysts saying about iRadimed Corporation? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for iRadimed Corporation and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit